...
首页> 外文期刊>American Journal of Physiology >P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.
【24h】

P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.

机译:心肌病的Calsequestrin模型的心肌细胞中P2X嘌呤能受体介导的离子电流:对心力衰竭的治疗意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

P2X purinergic receptors, activated by extracellular ATP, mediate a number of cardiac cellular effects and may be important under pathophysiological conditions. The objective of the present study was to characterize the P2X receptor-mediated ionic current and determine its role in heart failure using the calsequestrin (CSQ) model of cardiomyopathy. Membrane currents under voltage clamp were determined in myocytes from both wild-type (WT) and CSQ mice. The P2X agonist 2-methylthio-ATP (2-meSATP) induced an inward current that was greater in magnitude in CSQ than in WT ventricular cells. The novel agonist, MRS-2339, an N-methanocarba derivative of 2-chloro-AMP relatively resistant to nucleotidase, induced a current in the CSQ myocyte similar to that by 2-meSATP. When administered via a miniosmotic pump (Alzet), it significantly increased longevity compared with vehicle-injected mice (log rank test, P = 0.02). The improvement in survival was associated with decreases in the heart weight-to-body weight ratio and in cardiac myocyte cross-sectional area [MRS-2339-treated mice: 281 +/- 15.4 (SE) mum(2), n = 6 mice vs. vehicle-treated mice: 358 +/- 27.8 mum(2), n = 6 mice, P < 0.05]. MRS-2339 had no vasodilator effect in mouse aorta ring preparations, indicating that its salutary effect in heart failure is not because of any vascular unloading. The cardiac P2X current is upregulated in the CSQ heart failure myocytes. Chronic administration of a nucleotidase-resistant agonist confers a beneficial effect in the CSQ model of heart failure, apparently via an activation of the cardiac P2X receptor. Cardiac P2X receptors represent a novel and potentially important therapeutic target for the treatment of heart failure.
机译:由细胞外ATP激活的P2X嘌呤能受体介导许多心脏细胞效应,在病理生理条件下可能很重要。本研究的目的是使用心肌病的Calsequestrin(CSQ)模型表征P2X受体介导的离子电流并确定其在心力衰竭中的作用。在野生型(WT)和CSQ小鼠的肌细胞中均测定了电压钳下的膜电流。 P2X激动剂2-甲硫基ATP(2-meSATP)诱导的内向电流在CSQ中比在WT心室细胞中更大。新型激动剂MRS-2339是2-氯-AMP的N-甲基氨基甲酸酯衍生物,对核苷酸酶具有相对的抗性,它在CSQ心肌细胞中诱导的电流类似于2-meSATP。当通过微型渗透泵(Alzet)给药时,与经媒介物注射的小鼠相比,它的寿命大大延长(对数秩检验,P = 0.02)。存活率的提高与心脏重量与体重的比率以及心肌细胞横截面积的减少有关[MRS-2339处理的小鼠:281 +/- 15.4(SE)妈妈(2),n = 6小鼠与媒介物治疗的小鼠:358 +/- 27.8 mum(2),n = 6只小鼠,P <0.05]。 MRS-2339在小鼠主动脉环制剂中没有血管舒张作用,表明其在心力衰竭中的有益作用不是由于任何血管卸载。在CSQ心力衰竭心肌细胞中,心脏P2X电流上调。长期给予抗核苷酸酶的激动剂显然可以通过激活心脏P2X受体在心力衰竭的CSQ模型中产生有益的作用。心脏P2X受体代表了治疗心力衰竭的新型且潜在的重要治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号